Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
182
resultados
Última actualización
24/06/2025 [06:54:00]
Resultados 125 a 150 de 182
Resumen de: US2025186387A1
The present disclosure relates to a field of biomedical technology. Embodiments of the present disclosure provide a leonurine nanocomposite hydrogel and preparation method and application thereof, including: dissolving dopamine (DA) monomers and inducing oxidation and self-polymerization of the DA to obtain polydopamine (PDA) nanoparticles, grafting thiol polyethylene glycol folic acid (SH-PEG-FA) on a surface of the PDA nanoparticles to obtain folic acid polydopamine (FA-PDA) nanocarriers; loading a leonurine (Leon) using the FA-PDA nanocarriers of the step 1 to obtain FA-PDA@Leon; encapsulating the FA-PDA@Leon of the step 2 into a gel matrix to obtain gel@FA-PDA@Leon hydrogel.
Resumen de: US2025186361A1
The current invention relates to a method for manufacturing one or more carriers with one or more active pharmaceutical ingredients, wherein said method comprises mixing at least a solution comprising one or more active pharmaceutical ingredients with one or more organic solvents comprising one or more lipids and/or polymers, thereby forming a formulation comprising one or more carriers, and subsequently removing at least part of said one or more organic solvents by a pervaporation step. In a second aspect, said invention also relates to a system for manufacturing such carriers, wherein said system comprises a pervaporation device for removal of one or more organic solvents from a formulation comprising one or more carriers.
Resumen de: CN119546336A
Disclosed herein are compositions comprising allogeneic, low immunogenic chimeric antigen receptor (CAR)-targeting biomimetic nanovesicles (BioNVs), and methods of treating, preventing, and/or ameliorating cancer using the same.
Resumen de: CN119522092A
The present invention relates to nanoparticles, in particular nanoparticles suitable for delivery of nucleic acids to cells. The nanoparticles comprise multivalent molecules to stabilize nucleic acid molecules in the nanoparticles. In particular, the multivalent molecule has a dendrimer-like structure. The invention also relates to the manufacture of nanoparticles and the use of such nanoparticles in the treatment of disease.
Resumen de: CN119562807A
The present disclosure provides nucleic acid particles comprising an immunomodulator, RNA, and a cationic lipid or cationic polymer, wherein the nucleic acid particles described herein reduce inflammatory responses and/or increase protein or antigen expression associated with a previous formulation.
Resumen de: AU2025203628A1
The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.
Resumen de: AU2023375897A1
Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.
Resumen de: US2025186359A1
The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.
Resumen de: WO2025118118A1
Carbon monoxide core-shell nanoparticles capable of intravenous administration, a preparation method therefor, and use thereof, belonging to the technical field of nanomedicine. The preparation method for the carbon monoxide core-shell nanoparticles comprises: 1. preparing a polymer carrier PLGA(CO); 2. purifying the PLGA(CO); 3. weighing the PLGA(CO) and a functional material, dissolving them in THF, adding deionized water after ultrasonication, blowing off THF by using nitrogen, carrying out co-precipitation, centrifuging, washing, and carrying out co-precipitation to obtain a nanoparticle functional material @PLGA(CO); and 4. weighing DSPE-PEG, and reacting with the functional material @PLGA(CO) to obtain a functional material @PLGA(CO)@PEG. After a tail intravenous injection, the core-shell structure nanoparticles target a cancer site by means of intravenous injection under the monitoring of NIR-II fluorescence, and CO-enhanced mild temperature photothermal therapy is achieved to eliminate tumors.
Resumen de: WO2025118472A1
Provided is an anti-MET nanobody and an anti-EGFR nanobody, and a bispecific antibody comprising the two nanobodies. Also provided is a drug conjugate constructed on the basis of the nanobodies and the bispecific nanobody.
Resumen de: WO2025119217A1
Provided are a new cationic lipid compound, and a preparation method therefor, a composition thereof and the use thereof. The cationic lipid has a structure as represented by formula I. Lipid nanoparticles prepared from the cationic lipid have a stable nanostructure, have a relatively narrow size distribution, and can be stored for a relatively long time at a low temperature. Moreover, the lipid nanoparticles have relatively good biocompatibility and a relatively high in-vivo mRNA transfection efficiency. The core structures of the cationic lipids can all be constructed by means of a Ugi reaction. The reaction involves simple operation and mild reaction conditions, does not require additional catalysts, has high atomic economy, is simple and easy to carry out, and incorporates inexpensive and readily available raw materials, such that not only is higher safety provided, but the industrial production and quality control of the cationic lipids are also facilitated. The new cationic lipid has good application prospects.
Resumen de: WO2025122871A1
The present disclosure is directed, in some aspects, to oligonucleotide dendrimers comprising a molecular core covalently linked to one or more first oligonucleotide branches, wherein the molecular core is a polyethylene glycol (PEG) core, a polyester (PE) core, or a polyaminoamine (PAMAM) core. The disclosure also provides methods of making and/or using the oligonucleotide dendrimers for, e.g., treating a disease via inducing an immune response.
Resumen de: WO2025121735A1
The present invention relates to a nano-platform comprising core-shell structured upconversion nanoparticles, a composition comprising same, and a treatment method, the nano-platform comprising: a core formed of NaYF4:Yb, Tm through single-step synthesis; and a shell, which encompasses the core and is formed of NaYF4:Nd.
Resumen de: US2025186431A1
Provided is a pharmaceutical composition for use in radiotherapy, comprising: a compound represented by formula (I) wherein R1 is an aryl group substituted with a substituent selected from an iodine atom and others, wherein the aryl group is optionally substituted with a substituent such as a hydroxy group, X represents a bond or the like and ring A is a group represented by formula (A), wherein R2 is a non-aromatic heterocyclic group optionally substituted with at least one C1-C4 alkyl group, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. Also, provided is a nanoparticle and a method for treating solid cancer using the compound.
Resumen de: US2025188140A1
The present disclosure relates to a lipid-like nanoparticle encapsulating a C—C motif chemokine ligand 5 (CCL5) mRNA and methods of use thereof.
Resumen de: US2025188191A1
The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.
Resumen de: US2025188132A1
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
Resumen de: US2025186358A1
The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Resumen de: AU2023343598A1
Compounds, compositions, uses, and methods for reducing cell viability of a cancer cell, or for preventing or treating cancer, are provided herein. In certain examples, methods for reducing cell viability of a cancer cell and/or for preventing or treating cancer in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a
Resumen de: WO2024059630A2
The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprising a polynucleotide that encodes an interleukin-12 (IL-12) formulated with a lipopolymer (e.g., a nanoparticle). In some aspects, the method further comprises administering to the subject an anticancer agent (e.g., a chemotherapeutic agent), an antibody or antigen-binding fragment thereof that specifically binds a vascular endothelial growth factor (VEGF) (anti-VEGF antibody), an immune checkpoint inhibitor, or any combination thereof.
Resumen de: WO2024031027A2
Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of CTA epitope-encoding sequences or Cancer Testis Antigen (CTA)-encoding nucleic acid sequences and KRAS-encoding nucleic acid sequences. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.
Resumen de: GB2636076A
A lipid nanoparticle (liposome) comprising: (i) an outer shell comprising a lipid formulation; and (ii) one or more therapeutic agents which prevent apoptosis of a target cell is provided. The therapeutic agent may comprise one or more caspase inhibitors, such as Emricasan, or may comprise one or more siRNA which prevents or reduces the expression of a protein which induces or enhances apoptosis, such as NR3C1 or ADRB2. The lipid formulation may comprise hydrogenated soy phosphatidylcholine (HSPC), cholesterol (Chol) and 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-2000 (DSPE-PEG2000). The outer shell may further comprise 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaaceticacid (PE-DTPA). The lipid nanoparticle may further comprise a spleen-targeting moiety. The lipid nanoparticle (liposome) for use in treating or preventing a disease or disorder associated with spleen abnormality is provided. The disease or disorder is preferably a post post-brain injury infection, such as a stroke-associated infection. A method of treating a stroke-associated infection in a subjection by administrating the lipid nanoparticle is provided.
Resumen de: EP4566606A1
A specific silicon compound is represented by the following formula:wherein each symbol is as defined in the specification. A composition comprises the silicon compound and cetylpyridinium chloride hydrate and is in the form of nanoparticles. The composition can be easily attached to or carried by a medical material or a medical device in a favorable manner.
Resumen de: EP4566618A1
The present disclosure relates to therapeutic and non-therapeutic methods for obtaining or promoting weight loss in a mammal, especially in a human individual, comprising supplementing a cell of the mammal with a Klotho protein by administering to the cell a nucleic acid encoding the Klotho protein such that the nucleic acid is expressed within the cell to produce the Klotho protein so as to obtain weight loss in said mammal.
Nº publicación: EP4566672A2 11/06/2025
Solicitante:
CLEARSIDE BIOMEDICAL INC [US]
Clearside Biomedical Inc
Resumen de: EP4566672A2
Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
BOPI
Sede Electrónica
